Similar beneficial anti-tumor effects of combined ERRα and DNMT inhibitors were observed in the ER+ BC cell line MCF7 and TNBC cell lines MDA-MB-231, MDA-MB-436, and MDA-MB-468 (Fig. 4g–j and Supplementary Fig. 4a–d). Here, ESRRA is linked to breast cancer.